Moderna's success in a skin cancer vaccine also makes the Biontech share rise significantly. However, the company is loitering it. A trade unionist blames the top management.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Moderna's success in a skin cancer vaccine also makes the Biontech share rise significantly. However, the company is loitering it. A trade unionist blames the top management.